Trial Profile
Darunavir/Cobicistat and Dolutegravir to Maintain Virologic Suppression and Reduce NRTI-associated Toxicity (The 'deNUC' Study; TMC114HIV2030)
Status:
Active, no longer recruiting
Phase of Trial:
Phase II/III
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Cobicistat/darunavir (Primary) ; Dolutegravir (Primary)
- Indications HIV-1 infections
- Focus Therapeutic Use
- Acronyms deNUC
- 27 Oct 2016 Status changed from not yet recruiting to active, no longer recruiting.
- 23 Jul 2015 New trial record